GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » Price-to-Owner-Earnings

VIVUS (STU:VIU1) Price-to-Owner-Earnings : (As of May. 14, 2024)


View and export this data going back to . Start your Free Trial

What is VIVUS Price-to-Owner-Earnings?

As of today (2024-05-14), VIVUS's share price is €0.06. VIVUS does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for VIVUS's Price-to-Owner-Earnings or its related term are showing as below:


STU:VIU1's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.165
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-14), VIVUS's share price is €0.06. VIVUS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2020 was €-2.43. Therefore, VIVUS's PE Ratio for today is At Loss.

As of today (2024-05-14), VIVUS's share price is €0.06. VIVUS's EPS without NRI for the trailing twelve months (TTM) ended in was €-2.43. Therefore, VIVUS's PE Ratio without NRI for today is At Loss.


VIVUS Price-to-Owner-Earnings Historical Data

The historical data trend for VIVUS's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS Price-to-Owner-Earnings Chart

VIVUS Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.13 - - -

VIVUS Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VIVUS's Price-to-Owner-Earnings

For the Biotechnology subindustry, VIVUS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VIVUS's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIVUS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where VIVUS's Price-to-Owner-Earnings falls into.



VIVUS Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

VIVUS's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.06/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VIVUS  (STU:VIU1) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


VIVUS Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of VIVUS's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


VIVUS (STU:VIU1) Business Description

Industry
Traded in Other Exchanges
N/A
Address
900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines